Georgia's Online Cancer Information Center


back

Stomach/ Gastric Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Stomach/ Gastric Cancer
Cancer Type = Stomach/ Gastric Cancer
NCI ID Cancer Type Trial Name
There are currently 11 active Stomach/ Gastric Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Study of ASP1012 in Adults With Solid Tumors
Cancer Type
Melanoma, Stomach/ Gastric Cancer
NCT ID
NCT06171178
Protocol IDs
1012-CL-0101
NCI-2024-03269
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Stomach/ Gastric Cancer
NCT ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
4.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Stomach/ Gastric Cancer
NCT ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
5.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type
Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT06346392
Protocol IDs
D9802C00001
NCI-2024-05552
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
6.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
7.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
8.
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type
Stomach/ Gastric Cancer
NCT ID
NCT03257163
Protocol IDs
071702
NCI-2017-01429
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
9.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
10.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type
Lung Cancer, Melanoma, Stomach/ Gastric Cancer
NCT ID
NCT04198766
Protocol IDs
Ph 1 INBRX-106
NCI-2020-06313
MK3475 KEYNOTE A99
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
11.
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Cancer Type
Stomach/ Gastric Cancer
NCT ID
NCT04725994
Protocol IDs
ID-VDP-103
NCI-2021-09611
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.